Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-01-03Clinical Trial Update: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) [Phase 3]
This is a Phase 3 clinical trial (TWINS) evaluating withdrawal of disease-modifying therapies in inactive Relapsing-remitting Multiple Scler…
-
CLINICAL_TRIALS withdrawal · 2024-06-03Clinical Trial Update: A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a [Phase 4]
A Phase 4 proof-of-concept study evaluating retinal nerve fiber layer changes in relapsing-remitting multiple sclerosis patients treated wit…
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Accord (dimethyl fumarate) — Accord Healthcare S.L.U.
EMA revoked the marketing authorization for Dimethyl fumarate Accord for multiple sclerosis indications.
-
CLINICAL_TRIALS withdrawal · 2021-11-09Clinical Trial Update: A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 study comparing two oral doses of laquinimod to interferon beta-1a in relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS [Phase 4]
A Phase 4 trial evaluating the mechanism of action of dimethyl fumarate in relapsing multiple sclerosis has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-04-25Clinical Trial Update: Brimonidine Tartrate for the Treatment of Injection Related Erythema [Phase 4]
A Phase 4 study evaluating brimonidine tartrate for injection-related erythema in relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-04-13Clinical Trial Update: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]
A Phase 3 placebo-controlled study of BG00012 (dimethyl fumarate) in pediatric relapsing-remitting multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-04-06Clinical Trial Update: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 2]
Phase 2 proof-of-concept trial evaluating RNS60 for Relapsing-Remitting Multiple Sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-29Clinical Trial Update: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
A clinical trial comparing Rebif (interferon beta-1a) with Tecfidera (dimethyl fumarate) for six-month outcomes in relapsing-remitting multi…
-
CLINICAL_TRIALS withdrawal · 2015-12-28Clinical Trial Update: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis [Phase 4]
A Phase 4 trial evaluating the onset of efficacy of dimethyl fumarate (BG00012) in relapsing-remitting multiple sclerosis has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2015-09-07Clinical Trial Update: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate [Phase 4]
A Phase 4 clinical trial evaluating fatigue in people with relapsing-remitting multiple sclerosis treated with dimethyl fumarate has been wi…
-
CLINICAL_TRIALS withdrawal · 2014-09-30Clinical Trial Update: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS [Phase 4]
Novartis' Phase 4 trial evaluating an individualized patient support program for treatment satisfaction in fingolimod-treated Relapsing-remi…
-
CLINICAL_TRIALS withdrawal · 2014-09-15Clinical Trial Update: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating PEGylated interferon beta-1a (BIIB017) for Relapsing-Remitting Multiple Sclerosis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-02-20Clinical Trial Update: Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating simvastatin as an add-on therapy to Copaxone (glatiramer acetate) for relapsing-remitting multiple scler…
-
CLINICAL_TRIALS withdrawal · 2013-08-06Clinical Trial Update: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects [Phase 4]
Phase 4 implementation study evaluating treatment optimization recommendations for relapsing-remitting multiple sclerosis has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2012-04-16Clinical Trial Update: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
The clinical trial evaluating BETaferon for quality of life in early relapsing-remitting multiple sclerosis in Korea has been withdrawn.